Oral GLP-1 Pill Significantly Reduces Sleep Apnea Severity in Phase 3 Trials

Eli Lilly's oral GLP-1 medication, orforglipron, significantly reduced the severity of obstructive sleep apnea in adults with obesity or overweight, according to phase 3 trial results presented at the American Heart Association 2026 Scientific Sessions.[1]

The findings from the ATTAIN-OSA program, published simultaneously in JAMA on November 9, 2026, demonstrated that the daily pill reduced breathing interruptions by up to 44 percent over 52 weeks. Up to 31.5 percent of participants achieved disease remission or mild disease.[1][3]

"If approved to treat obstructive sleep apnea, orforglipron could be a promising oral pharmacologic option for people with overweight or obesity and this condition," said Dr. Vaishnavi Kundel of the Icahn School of Medicine at Mount Sinai, who presented the findings.[1][2]

Trial Design and Efficacy

The ATTAIN-OSA program consisted of two independent 52-week studies involving 712 participants with moderate-to-severe sleep apnea and a body mass index of 27 or higher. None of the enrolled participants had type 1 or type 2 diabetes.[1][4]

The first study enrolled 363 individuals who were unable or unwilling to use continuous positive airway pressure therapy. The second study included 349 participants who were already using a CPAP machine and planned to continue the intervention.[1][3]

Among patients not using CPAP, those taking orforglipron saw their apnea-hypopnea index fall by 21.1 events per hour. This represented a 43.8 percent reduction from baseline, compared with a decrease of just 4.3 events per hour in the placebo group.[2]

For participants who continued using CPAP therapy, the medication reduced the apnea-hypopnea index by 18.3 events per hour. The placebo group in this cohort experienced a decrease of 5.5 events per hour over the same 52-week period.[2]

Beyond the primary endpoint, the medication significantly reduced the sleep apnea-specific hypoxic burden. This secondary metric measures exactly how deeply and for how long a patient's blood oxygen levels fall during sleep due to airway collapse.[2][3]

Hypoxic burden decreased by 55.9 percent in the non-CPAP group and by 45.8 percent among those using CPAP. Repeated oxygen deprivation during sleep is closely linked to severe cardiovascular risks, including treatment-resistant hypertension, heart failure, and stroke.[3]

Cardiometabolic Benefits

The trial results support the prevailing theory that drug-mediated weight loss is a primary mechanism for improving sleep apnea severity. However, researchers noted that weight reduction may not be the only factor driving the physiological changes in the airway.[1]

Participants taking orforglipron lost an average of 10 to 11 percent of their body weight over the 52-week period. In contrast, those receiving a placebo saw only a 1 to 2 percent reduction in body weight during the trial.[1]

The medication also delivered notable cardiovascular benefits independent of respiratory metrics. Systolic blood pressure fell by about seven points after one year of treatment, a reduction that researchers described as clinically meaningful for long-term heart health.[2]

"Previous research has confirmed that using CPAP devices while sleeping can help lower blood pressure by about two to three points," Kundel noted. She emphasized that the seven-point drop represents a substantial additive cardiovascular protection provided by the oral therapy.

Blood tests revealed a substantial drop in high-sensitivity C-reactive protein, a key biomarker of systemic inflammation. The marker fell by 48.9 percent in the non-CPAP group and 38.6 percent in the CPAP group over the course of the year.[2]

Safety and Tolerability

The safety profile of orforglipron in the ATTAIN-OSA trials remained consistent with previous studies of the medication. Gastrointestinal issues emerged as the most common adverse events reported by participants across both independent study cohorts during the 52-week period.[1][3]

Participants frequently reported mild to moderate nausea, diarrhea, and constipation. These side effects are typical of the GLP-1 receptor agonist class and generally subside as the patient's body adjusts to the medication over the first few months.[3]

Treatment discontinuation due to adverse events was higher among those taking the active drug. In the non-CPAP cohort, 12.2 percent of orforglipron users discontinued treatment entirely, compared with just 3.8 percent of patients on the placebo.[3]

Discontinuation rates were notably lower in the CPAP cohort, where 6.8 percent of participants on orforglipron dropped out due to side effects. Only 0.6 percent of the placebo group in this cohort chose to discontinue their treatment.[3]

Expanding Treatment Options

Currently, Eli Lilly's injectable medication Zepbound is the only GLP-1 drug approved by the US Food and Drug Administration specifically for moderate-to-severe obstructive sleep apnea. The regulatory agency granted that landmark indication to the tirzepatide injection in late 2024.[1][3]

While the injectable tirzepatide demonstrated greater improvements in apnea-hypopnea index and hypoxic burden in its own trials, the format has drawbacks. The requirement for cold-chain storage and weekly injections presents a persistent barrier for some patients.[2]

"The biggest benefit of orforglipron is really the fact that it comes in a tablet form, for once-daily administration," noted Dr. Ildiko Lingvay. She highlighted the distinct accessibility advantages of an oral formulation over traditional biologics.[2]

An oral therapy could prove particularly valuable in under-resourced healthcare settings or for individuals who experience needle aversion. This daily pill format could significantly broaden the global reach of GLP-1 treatments for severe respiratory conditions.[4]

AI

Eli Lilly plans to submit the ATTAIN-OSA data to the FDA by the end of 2026. The pharmaceutical company is seeking a formal label expansion for orforglipron in adults with moderate-to-severe sleep apnea and obesity or overweight.[3]

If approved, Foundayo would become the first oral GLP-1 medication explicitly indicated for sleep apnea. It would position itself as a highly convenient alternative to both injectable weight-loss drugs and the traditional mechanical CPAP machines that dominate current care.[2][3]

The company is also awaiting regulatory decisions for orforglipron in weight management and type 2 diabetes. Eli Lilly filed for US review in those primary metabolic indications earlier in the year and expects a response soon.[3]

Addressing a Global Burden

Obstructive sleep apnea affects an estimated 936 million adults worldwide. Despite the severe cardiovascular risks associated with the condition, the vast majority of global cases remain completely undiagnosed and untreated by medical professionals, leaving patients vulnerable to complications.

The condition is characterized by the repeated collapse of the upper airway during sleep. This mechanical failure fragments rest and places chronic stress on the cardiovascular system through repeated oxygen desaturation events that occur throughout the night.[1]

While CPAP therapy remains the gold standard for maintaining an open airway, adherence rates are notoriously low. Many patients find the bedside machine and pressurized mask deeply uncomfortable or disruptive to their natural sleep patterns.[4]

The ATTAIN-OSA results suggest that pharmacological interventions could serve a dual purpose in clinical practice. They may act as an alternative for patients who cannot tolerate CPAP or as an adjunctive therapy to enhance overall disease management.[1][4]

Researchers cautioned that the trials did not evaluate outcomes beyond one year and excluded individuals with diabetes. These limitations underscore the pressing need for longer-term studies in more diverse patient populations to confirm sustained cardiovascular outcomes.[1][4]

The American Heart Association currently counts healthy sleep among its core "Life's Essential 8" measures of cardiovascular health. The organization strongly recommends routine screening for sleep apnea in people presenting with certain high-risk cardiovascular conditions like atrial fibrillation.

As pharmaceutical options for sleep apnea expand, clinical guidelines may need to adapt rapidly. The integration of oral weight-management medications into respiratory care represents a fundamental shift in how specialists approach and treat the mechanical condition.[2]